Baloxavir Marboxil CAS 1985606-14-1
Baloxavir Marboxil (CAS 1985606 14 1) is a first in class antiviral for treating uncomplicated influenza in appropriate patients.
what's Baloxavir Marboxil CAS 1985606-14-1?
Baloxavir Marboxil is a novel influenza antiviral prodrug that is rapidly converted in vivo into its active metabolite, baloxavir acid. It functions as a cap-dependent endonuclease inhibitor, targeting the PA subunit of the influenza virus polymerase complex.
Unlike neuraminidase inhibitors such as oseltamivir, Baloxavir acts at an early stage of viral replication by blocking viral mRNA transcription. This differentiated mechanism makes it a key molecule in modern influenza drug development and generic API manufacturing.
We supply high-purity Baloxavir Marboxil API (≥98%) suitable for pharmaceutical research, formulation development, and bulk procurement.
Technical Specification
| Item | Specification |
|---|---|
| Chemical Name | Baloxavir Marboxil |
| CAS Number | 1985606-14-1 |
| Molecular Formula | C27H23F2N3O7S |
| Molecular Weight | 571.55 g/mol |
| Appearance | White to off-white crystalline powder |
| Purity | ≥98% (HPLC) |
| Solubility | Slightly soluble in water |
| Storage | 2–8°C, protected from light |
Key Benefits of Baloxavir Marboxil
- Broad activity against influenza A and B
- Innovative polymerase-targeting mechanism
- Early viral replication suppression
- Clinically validated antiviral compound
- Ideal reference standard for cap-dependent endonuclease inhibition studies
- Suitable for generic drug development projects
Applications of Baloxavir Marboxil
Baloxavir Marboxil is widely used in:
- Influenza antiviral drug development
- Generic formulation and reverse engineering programs
- Polymerase inhibitor research
- Viral resistance mutation studies
- Pharmaceutical API bulk procurement
It is an essential molecule in next-generation antiviral pipelines targeting RNA virus replication.
Mechanism of Action
Baloxavir Marboxil is an oral prodrug that is metabolized into baloxavir acid after administration.
The active compound:
- Selectively binds to the PA endonuclease domain
- Inhibits the cap-snatching process
- Blocks viral mRNA transcription
- Prevents influenza viral replication
This early-stage inhibition distinguishes Baloxavir from traditional neuraminidase inhibitors that act during viral release.
Side Effects
Baloxavir Marboxil is generally well-tolerated as an influenza antiviral in clinical studies, but like all pharmaceuticals, it may be associated with some adverse effects. These are mostly mild to moderate and transient:
- Gastrointestinal Effects: Nausea, diarrhea, abdominal pain
- Respiratory Symptoms: Nasopharyngitis, cough, or upper respiratory tract infections
- Neurological Effects: Headache or dizziness in rare cases
- Skin Reactions: Occasional rash or mild hypersensitivity
- Other Observations: Rare instances of elevated liver enzymes
Notes:
Adverse effects are usually mild and resolve without intervention.
Serious side effects are extremely rare.
The safety profile is primarily based on controlled clinical studies of baloxavir in adults and pediatric populations.
Always follow local regulations and research guidelines when handling and using API-grade material.
Comparison: Baloxavir vs Oseltamivir
| Feature | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Target | PA Endonuclease | Neuraminidase |
| Stage of Action | Early transcription | Viral release |
| Mechanism Type | Polymerase inhibitor | NA inhibitor |
| Resistance Focus | PA mutations | NA mutations |
FAQ
What is the CAS number of Baloxavir Marboxil?
CAS 1985606-14-1.
What Does Baloxavir Marboxil Do?
Baloxavir Marboxil is a prodrug converted into baloxavir acid, which blocks influenza virus replication by inhibiting the viral cap-dependent endonuclease. This stops viral mRNA production, reduces viral load, and shortens flu symptoms.
Is this product suitable for pharmaceutical formulation?
Yes, it is supplied as high-purity API material suitable for research and development.
How is Baloxavir different from neuraminidase inhibitors?
Baloxavir inhibits viral RNA transcription at an earlier stage of replication, while neuraminidase inhibitors block viral release.
Do you provide bulk quantities?
Yes, we support gram-to-kilogram scale supply depending on project needs.
Why Choose Us as Your Baloxavir Marboxil Supplier?
- High purity ≥98% verified by HPLC
- Strict quality control and batch consistency
- COA and analytical documentation available
- Competitive bulk pricing
- Reliable global shipping
- Professional support for pharmaceutical companies and R&D institutions
certifications
Shipping methods
| Country | Delivery time |
| Untied states | 7-15 DAYS |
| Australia | 7-12 DAYS |
| Germany | 7-12 DAYS |
| Canada | 8-10 DAYS |
| New zealand | 7-10 DAYS |
| Uk | 5-10 DAYS |
| Thailand | 5-8 DAYS |
| Malaysia | 5-8 DAYS |
| Vietnam | 5-8 DAYS |
The delivery time shown above is an estimate. Shipping routes and freight capacity may change from time to time. For the most accurate delivery schedule, please contact us directly.
Payment terms
delivery records
Message us to get your personalized quotation within 24 hours.
-
Whatsapp:+852 6736 4057
-
Telegram:@hinovopept
-
Email:novopept@gmail.com
Hottags：
Baloxavir Marboxil API, Baloxavir Marboxil bulk powder, Baloxavir Marboxil CAS 1985606-14-1,Baloxavir Marboxil for pharma manufacturin, raw material, Baloxavir Marboxil adult & adolescent use
Baloxavir Marboxil quality 99%, Baloxavir Marboxil GMP grade, Baloxavir Marboxil supplier China, Baloxavir Marboxil export, Baloxavir Marboxil global shipping,Baloxavir Marboxil safe storage Baloxavir Marboxil high purity
Hot Tags: baloxavir marboxil cas 1985606-14-1, China baloxavir marboxil cas 1985606-14-1 manufacturers, suppliers, factory
Send Inquiry
